Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PRCH vs SKIN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PRCH Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 9–1 Matrix Metrics)

PRCH Overall Winner 6-Pillar Tally: PRCH 4 – 2 SKIN Matrix Metrics: PRCH 9 – 1 SKIN

As of Nov 16, 2026, Porch Group, Inc. (PRCH) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PRCH carries a Unified Composite Score of 47.3/100 (HOLD) at $20.92 (62.6x Forward P/E, 8.0% operating margin), whereas SKIN carries 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PRCH vs SKIN
PRCH NASDAQ Head-to-Head Winner
Porch Group, Inc. Common Stock
Services-Prepackaged Software
$20.92
-0.62% 1D
Market Cap $2.4B
TTM Revenue $530M
Forward P/E 62.6x
Beta / 30D Vol 1.59β · 114% Vol
Unified Composite Score
47.3 / 100 HOLD
Tech 26.0 Fund 45.0 Flow 55.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.6% over 20 days), RSI 58
RSI-14: 57.9 · SMA20: $19.83 · SMA50: $18.02
SKIN NASDAQ
The Beauty Health Company Class A Common Stock
Surgical & Medical Instruments & Apparatus
$15.05
-7.73% 1D
Market Cap $106.3M
TTM Revenue $289M
Forward P/E 106.4x
Beta / 30D Vol -14.22β · 192% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (314.8% over 20 days), RSI 67
RSI-14: 67.4 · SMA20: $12.50 · SMA50: $6.24

6-Pillar Scorecard Institutional Category Breakdown (PRCH 4 – 2 SKIN)

Columns: Metric · PRCH · SKIN
1. Valuation Multiples SKIN
Forward P/E 62.6x 106.4x
Trailing P/E N/M 106.4x
PEG Ratio N/M 0.93x
EV / Revenue 4.9x 0.9x
2. Growth & Scale PRCH
Revenue Growth (YoY) +13.0% -2.1%
Earnings Growth (YoY) +155.3% +0.0%
TTM Revenue (USD) $530M $289M
Market Cap $2.4B $106.3M
3. Profitability & Quality PRCH
Gross Margin 72.1% 67.2%
Operating Margin 8.0% 2.4%
Net Profit Margin 1.8% -6.3%
Return on Equity (ROE) 5.6% -30.1%
4. Balance Sheet & Cash Flow PRCH
Cash Generation (TTM) $99M $17M
Cash Flow Margin 18.6% 5.8%
Net Cash / Leverage $181M Net Debt (53.60x D/E) $161M Net Debt (6.61x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PRCH
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 63.6% (13th %ile) 517.4% (100th %ile)
Put/Call OI Skew 0.02x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat SKIN
OpEx & R&D Intensity 64.1% of Rev ($340M) 64.8% of Rev ($187M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Insurance - Property & Casualty Operator Household & Personal Products Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PRCH (9) vs SKIN (1)
Institutional Metric PRCH SKIN Criterion Row Edge
Market Capitalization
Scale
$2.4B $106.3M Larger Scale PRCH
Trailing P/E Ratio
Valuation
N/M 106.4x Lower Multiple SKIN
Forward P/E Ratio
Valuation
62.6x 106.4x Lower Multiple PRCH
Revenue Growth (YoY)
Growth
+13.0% -2.1% Higher Growth PRCH
Operating Margin (TTM)
Profitability
8.0% 2.4% Higher Margin PRCH
Net Profit Margin
Profitability
1.8% -6.3% Higher Margin PRCH
Return on Equity (ROE)
Capital Efficiency
5.6% -30.1% Higher ROE PRCH
52-Week Range Position
Momentum
91% ($6–$22) 83% ($0–$18) Stronger Trend PRCH
Beta / 30D Volatility
Risk Regime
1.59β · 114% Vol -14.22β · 192% Vol Lower Realized Risk PRCH
Unified Institutional Score
Composite Signal
47.3 / 100 (HOLD) 34.1 / 100 (SELL) Higher Composite PRCH
Trailing 12M Revenue (USD)
Operating Scale
$530M $289M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
72.1% 67.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.9x EV/Rev 0.93x PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$99M ($181M Net Debt (53.60x D/E)) $17M ($161M Net Debt (6.61x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SKIN +22.98 pp
PRCH: +19.54% · SKIN: +42.52%
3M Horizon SKIN +2382.91 pp
PRCH: +25.42% · SKIN: +2408.33%
6M Horizon SKIN +2275.31 pp
PRCH: +109.83% · SKIN: +2385.14%
1Y Horizon SKIN +952.59 pp
PRCH: +105.1% · SKIN: +1057.69%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PRCH Revenue SKIN Revenue PRCH Op. Margin SKIN Op. Margin Margin Leader
FY2019 $80M $170M -113.6% 8.1% SKIN
FY2020 $70M $120M -58.4% -14.4% SKIN
FY2021 $190M $260M -43.3% -15.4% SKIN
FY2022 $280M $370M -64.2% -7.1% SKIN
FY2023 $290M $400M -66.2% -32.9% SKIN
FY2024 $310M $330M -20.6% -20.3% SKIN
FY2025 $420M $300M 8.7% -6.9% PRCH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PRCH BREAKOUT
96d in phase · OBV ACCUMULATION
Current IV 63.6%
IV Percentile 13th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PRCH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SKIN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 517.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact SKIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PRCH Moat Profile Cyclical / Execution-Driven Positioning
Insurance - Property & Casualty Operator
Competes within the Insurance - Property & Casualty value chain with $2.4B market capitalization and 8.0% operating margin.
OpEx & R&D Reinvestment 64.1% of Rev ($340M)
90D Engineering Disclosures 0 Published
SKIN Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $106.3M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($187M)
90D Engineering Disclosures 0 Published

Investor FAQ PRCH vs SKIN Key Questions & Quantitative Answers

As of Nov 16, 2026, Porch Group, Inc. (PRCH) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PRCH carries a Unified Composite Score of 47.3/100 (HOLD) at $20.92 (62.6x Forward P/E, 8.0% operating margin), whereas SKIN carries 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin). Technically, PRCH sits in a Markup phase (RSI 57.9, BREAKOUT options structure) and SKIN sits in a Markup phase (RSI 67.4, UNCLASSIFIED options structure).

PRCH leads the Growth & Scale pillar: PRCH posts +13.0% YoY revenue growth and +155.3% YoY earnings growth on $530M TTM revenue (72.1% gross margin, 8.0% operating margin), compared with SKIN at -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), PRCH cumulative revenue shifted +425.0% while SKIN shifted +76.5%. In operating R&D and SG&A reinvestment, PRCH deploys 64.1% of Rev ($340M) (0 90-day corporate R&D disclosures) versus 64.8% of Rev ($187M) (0 disclosures) for SKIN.

SKIN screens cheaper on headline valuation multiples. PRCH trades at 62.6x Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (18.6% FCF margin), whereas SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PRCH (5.6% ROE) versus SKIN (-30.1% ROE) capital efficiency.

In options market volatility and institutional positioning, PRCH carries 63.6% implied volatility (13th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.59β · 114% Vol realized risk). By comparison, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.